Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1978 Dec;38(6):674–684. doi: 10.1038/bjc.1978.272

A study of false positive and negative responses in the tube leucocyte adherence inhibition (tube LAI) assay.

R O'Connor, J K MacFarlane, D Murray, D M Thomson
PMCID: PMC2009817  PMID: 369586

Abstract

A panel of 5 different breast-cancer and 2 other cancer extracts was used to clarify the false-negative responses in patients with Stage I and II breast cancer and the false-positive responses in control subjects. Most patients with Stage I and II breast cancer who had an initially negative LAI response were positive when tested against the panel. The false negatives occurred because of (1) the experimental errors of the assay; (2) changes in the antigenic strength of the extracts; (3) antigenic heterogeneity of a few tumours and (4) lack of tumour-specific reactivity of the host. 3% of control subjects had a false-positive LAI response. The leucocytes from most of these positive patients did not react to the panel of antigens, and hence the false positives appeared to result from experimental error. In-hospital patients with benign breast disease had a 12% positivity rate when initially assayed, and 63% of these patients reacted to the panel of breast-cancer antigens. Those patients with benign breast disease who reacted to the panel of breast-cancer antigens had cytophilic anti-breast-cancer antibody in their serum; their leucocyte LAI reactivity was blocked in an immunologically specific manner by serum from advanced Stage IV breast-cancer patients; their leucocytes reacted to extracts of breast cancer and not fibrocystic breast tissue; their leucocyte reactivity was blocked by isolated breast-cancer TSA that was linked to beta 2 microglobulin, but not by normal breast-tissue proteins; and the kinetics of the LAI response after excision of the breast mass was identical to that observed with breast-cancer patients after mastectomy. In these patients, the breast tissue within the breast lump expressed breast TSA similar to unequivocal breast cancer.

Full text

PDF
674

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black M. M., Barclay T. H., Cutler S. J., Hankey B. F., Asire A. J. Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer. Cancer. 1972 Feb;29(2):338–343. doi: 10.1002/1097-0142(197202)29:2<338::aid-cncr2820290212>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  2. Brem S. S., Gullino P. M., Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science. 1977 Mar 4;195(4281):880–882. doi: 10.1126/science.402692. [DOI] [PubMed] [Google Scholar]
  3. Byers V. S., Levin A. S., Hackett A. J., Fudenberg H. H. Tumor-specific cell-mediated immunity in household contacts of cancer patients.. J Clin Invest. 1975 Mar;55(3):500–513. doi: 10.1172/JCI107956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Donnelly P. K., Baker K. W., Carney J. A., O'Fallon W. M. Benign breast lesions and subsequent breast carcinoma in Rochester, Minnesota. Mayo Clin Proc. 1975 Nov;50(11):650–656. [PubMed] [Google Scholar]
  5. Fazekas A. G., MacFarlane J. K. Macromolecular binding of glucocorticoids in human mammary carcinoma. Cancer Res. 1977 Mar;37(3):640–645. [PubMed] [Google Scholar]
  6. Flores M., Marti J. H., Grosser N., MacFarlane J. K., Thomson D. M. An overview: antitumor immunity in breast cancer assayed by tube leukocyte adherence inhibition. Cancer. 1977 Feb;39(2):494–505. doi: 10.1002/1097-0142(197702)39:2<494::aid-cncr2820390218>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  7. Graham-Pole J., Ogg L. J., Ross C. E., Cochran A. J. Sensitisation of neuroblastoma patients and related and unrelated contacts to neuroblastoma extracts. Lancet. 1976 Jun 26;1(7974):1376–1379. doi: 10.1016/s0140-6736(76)93027-0. [DOI] [PubMed] [Google Scholar]
  8. Grosser N., Thompson D. M. Tube leukocyte (monocyte) adherence inhibition assay for the detection of anti-tumour immunity. III. "Blockade" of monocyte reactivity by excess free antigen and immune complexes in advanced cancer patients. Int J Cancer. 1976 Jul 15;18(1):58–66. doi: 10.1002/ijc.2910180109. [DOI] [PubMed] [Google Scholar]
  9. Grosser N., Thomson D. M. Cell-mediated antitumor immunity in breast cancer patients evaluated by antigen-induced leukocyte adherence inhibition in test tubes. Cancer Res. 1975 Sep;35(9):2571–2579. [PubMed] [Google Scholar]
  10. Haagensen C. D. The relationship of gross cystic disease of the breast and carcinoma. Ann Surg. 1977 Mar;185(3):375–376. doi: 10.1097/00000658-197703000-00020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  12. Lopez M. J., Thomson D. M. Isolation of breast cancer tumour antigen from serum and urine. Int J Cancer. 1977 Dec 15;20(6):834–848. doi: 10.1002/ijc.2910200604. [DOI] [PubMed] [Google Scholar]
  13. Lopez M., O'Connor R., MacFarlane J. K., Thomson D. M. The natural history of antitumour immunity in human breast cancer assayed by tube leucocyte adherence inhibition. Br J Cancer. 1978 Dec;38(6):660–673. doi: 10.1038/bjc.1978.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Marti J. H., Grosser N., Thomson D. M. Tube leukocyte adherence inhibition assay for the detection of anti-tumour immunity. II. Monocyte reacts with tumour antigen via cytophilic anti-tumour antibody. Int J Cancer. 1976 Jul 15;18(1):48–57. doi: 10.1002/ijc.2910180108. [DOI] [PubMed] [Google Scholar]
  15. Marti J. H., Thomson D. M. Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition. Br J Cancer. 1976 Aug;34(2):116–133. doi: 10.1038/bjc.1976.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Monson R. R., Yen S., MacMahon B. Chronic mastitis and carcinoma of the breast. Lancet. 1976 Jul 31;2(7979):224–226. doi: 10.1016/s0140-6736(76)91026-6. [DOI] [PubMed] [Google Scholar]
  17. Morton D. L., Malmgren R. A. Human osteosarcomas: immunologic evidence suggesting an associated infectious agent. Science. 1968 Dec 13;162(3859):1279–1281. doi: 10.1126/science.162.3859.1279. [DOI] [PubMed] [Google Scholar]
  18. Thomson D. M., Gold P., Freedman S. O., Shuster J. The isolation and characterization of tumor-specific antigens of rodent and human tumors. Cancer Res. 1976 Sep;36(9 Pt 2):3518–3525. [PubMed] [Google Scholar]
  19. Thomson D. M., Rauch J. E., Weatherhead J. C., Friedlander P., O'Connor R., Grosser N., Shuster J., Gold P. Isolation of human tumour-specific antigens associated with beta2 microglobulin. Br J Cancer. 1978 May;37(5):753–775. doi: 10.1038/bjc.1978.114. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES